Handelsbanken Fonder AB Makes New $243,000 Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Handelsbanken Fonder AB purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,792 shares of the company's stock, valued at approximately $243,000.

Other large investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its position in shares of Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after acquiring an additional 1,045,305 shares during the period. Asset Management One Co. Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares during the period. V Square Quantitative Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 21.8% during the 4th quarter. V Square Quantitative Management LLC now owns 19,802 shares of the company's stock valued at $439,000 after buying an additional 3,549 shares in the last quarter. Principal Financial Group Inc. grew its stake in Teva Pharmaceutical Industries by 3.1% in the 4th quarter. Principal Financial Group Inc. now owns 92,471 shares of the company's stock valued at $2,038,000 after acquiring an additional 2,752 shares during the period. Finally, Sanctuary Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 132.4% in the 4th quarter. Sanctuary Advisors LLC now owns 81,643 shares of the company's stock worth $1,799,000 after acquiring an additional 46,514 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.49% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TEVA. Bank of America raised their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Finally, Truist Financial started coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus target price of $24.44.

Teva Pharmaceutical Industries Stock Up 3.0%

Shares of Teva Pharmaceutical Industries stock traded up $0.51 during trading on Monday, reaching $17.50. The company had a trading volume of 9,484,772 shares, compared to its average volume of 10,185,356. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm's fifty day moving average is $16.04 and its 200-day moving average is $17.42. The company has a market cap of $20.07 billion, a price-to-earnings ratio of -12.07, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.48 earnings per share. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.